| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/27/2010 | EP1206563B1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 01/27/2010 | CN101636179A Antagonists of PCSK9 |
| 01/27/2010 | CN101636178A Thermoreversible oil-in-water emulsion |
| 01/27/2010 | CN101636177A Recombinant modified vaccinia virus ankara (MVA)-based vaccine for the avian flu |
| 01/27/2010 | CN101636176A Tissue targeted antigenic activation of the immune response to treat cancers |
| 01/27/2010 | CN101633907A Amplification culture method for antigen specific cytotoxic t lymphocytes |
| 01/27/2010 | CN101633689A Peptide selection method |
| 01/27/2010 | CN101632833A Prostatic cancer related gene and application thereof |
| 01/27/2010 | CN101632676A Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/27/2010 | CN100584948C Procine circoviruses, vaccines and diagnostic reagents |
| 01/27/2010 | CN100584946C Method of humanizing immune system molecules |
| 01/27/2010 | CN100584858C RA antigenic peptides |
| 01/27/2010 | CN100584380C Production of gamma immune protein capsules |
| 01/27/2010 | CN100584379C Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| 01/27/2010 | CN100584378C Use of mycobacterium antigen MPB64 in preparing product for locally detecting active tuberculosis |
| 01/27/2010 | CN100584377C Method for preparing vaccine to chicken coccidiosis |
| 01/27/2010 | CN100584331C Use of immunomudulatory compounds in preparing medicine for the treatment, control or prevention of myeloproliferative diseases |
| 01/26/2010 | US7652026 Pharmaceutical composition |
| 01/26/2010 | US7651998 administering a Venezuelan Equine Encephalitis (VEE) vector (alpha virus vector) comprising a heterologus nucleotide sequence to a subject; concurrently administering an antibody that specifically binds to the E1 and/or the E2 glycoprotein of the VEE vector to produce immune response to cancer patient |
| 01/26/2010 | US7651857 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 01/26/2010 | US7651854 Administering PC cell-derived growth factor (PCDGF); improves the efficiency of primary hematopoietic cell culture |
| 01/26/2010 | US7651842 Imunogenic complex comprising ribosomes |
| 01/26/2010 | US7651689 Methods of applying ionization radiation for therapy of infections |
| 01/26/2010 | US7651688 Method of modulating the activity of functional immune molecules to CD52 |
| 01/26/2010 | US7651687 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
| 01/26/2010 | US7651686 Enhancement of immune responses by 4-1bb-binding agents |
| 01/26/2010 | US7651678 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 01/26/2010 | CA2642066C Immuno-interactive fragments of the .alpha.c subunit of inhibin |
| 01/26/2010 | CA2465206C Polymeric thiol-linked prodrugs |
| 01/26/2010 | CA2421588C Tnf receptor-like molecules and uses thereof |
| 01/26/2010 | CA2394188C Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/26/2010 | CA2383105C Intranasal influenza virus vaccine |
| 01/26/2010 | CA2348928C Lps with reduced toxicity from genetically modified gram negative bacteria |
| 01/26/2010 | CA2328803C Anti-procalcitonin antibodies and the preparation and use thereof |
| 01/26/2010 | CA2301499C T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof |
| 01/26/2010 | CA2230033C Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| 01/26/2010 | CA2213500C Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 01/26/2010 | CA2204666C Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| 01/26/2010 | CA2201841C Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| 01/21/2010 | WO2010009346A2 Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| 01/21/2010 | WO2010009277A2 Immunogenic amphipathic peptide compositions |
| 01/21/2010 | WO2010009129A2 Methods of treating autoimmune diseases using cd4 antibodies |
| 01/21/2010 | WO2010009106A1 Advanced methods and systems for treating cell proliferation disorders |
| 01/21/2010 | WO2010008862A2 Live attenuated catfish vaccine and method of making |
| 01/21/2010 | WO2010008782A1 Non-hemolytic llo fusion proteins and methods of utilizing same |
| 01/21/2010 | WO2010008726A1 Novel synergistic effects |
| 01/21/2010 | WO2010008554A2 Methods and products for treating proliferative diseases |
| 01/21/2010 | WO2010008528A2 Marek's disease virus vaccine compositions and methods of using thereof |
| 01/21/2010 | WO2010008411A1 Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| 01/21/2010 | WO2010008113A1 Anti-cancer composition comprising a culture fluid of lactobacillus casei as an effective component |
| 01/21/2010 | WO2010008084A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | WO2010008075A1 Anti-system asc amino acid transporter 2 (asct2) antibody |
| 01/21/2010 | WO2010008051A1 Anti-human clcp1 antibody and use thereof |
| 01/21/2010 | WO2010007701A1 Therapeutic agent and test agent for disease with myocardial necrosis |
| 01/21/2010 | WO2010007463A1 Human cytomegalovirus neutralising antibodies and use thereof |
| 01/21/2010 | WO2010007365A1 Immunotherapeutic method |
| 01/21/2010 | WO2010007082A1 Compositions and methods of use for therapeutic antibodies |
| 01/21/2010 | WO2010007000A1 Cancerous disease modifying antibodies |
| 01/21/2010 | WO2010006720A1 Anti-amyloid immunogenic compositions, methods and uses |
| 01/21/2010 | WO2010006607A1 Vaccines comprising tb10.4 |
| 01/21/2010 | WO2010006452A1 New influenza virus immunizing epitope |
| 01/21/2010 | WO2010006447A1 Chimeric respiratory syncytial virus polypeptide antigens |
| 01/21/2010 | WO2010006438A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| 01/21/2010 | WO2009143168A3 Vaccine assays |
| 01/21/2010 | WO2009134027A3 Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same |
| 01/21/2010 | WO2009130612A3 Prion epitopes and methods of use thereof |
| 01/21/2010 | WO2009130506A3 Compounds for use in therapy |
| 01/21/2010 | WO2009129374A3 Methods and compositions for preventing adhesion |
| 01/21/2010 | WO2009117706A3 Methods of treatment using anti-mif antibodies |
| 01/21/2010 | WO2009117116A3 Heat shock protein gp96 vaccination and methods of using same |
| 01/21/2010 | WO2009104911A4 Uses as agents for prophylaxis or treatment of cervical cancer |
| 01/21/2010 | WO2009103319A3 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases |
| 01/21/2010 | WO2009086203A3 Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment |
| 01/21/2010 | WO2006039470A9 Anti- amyloid antibodies, compositions, methods and uses |
| 01/21/2010 | WO2004024097A9 Compositions and methods for the treatment of immune related diseases |
| 01/21/2010 | WO2003061561A9 Epsilon immunoglobulin chain derived peptides for induction of anti-ige antibodies |
| 01/21/2010 | US20100017900 Prostate Epithelial Androgen Receptor Suppresses Prostate Growth and Tumor Invasion |
| 01/21/2010 | US20100016572 Derived from the N-terminal domain of the serine-repeat antigen produced by the malaria parasite, Plasmodium falciparum; can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region; inhibit fever and cerebral malaria |
| 01/21/2010 | US20100016560 Monoclonal antibody that binds to an epitope of the lipopolysaccharide (LPS) inner core of Neisseria meningitidis for prevention and treatment of neisserial infections |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016549 Peyer's patch and/or m-cell targeting ligands |
| 01/21/2010 | US20100016424 Production and use of derivatized homoserine lactones |
| 01/21/2010 | US20100016415 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines |
| 01/21/2010 | US20100015597 Production of biological carriers for induction of immune response and inhibition of viral replication |
| 01/21/2010 | US20100015593 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 01/21/2010 | US20100015238 Powder Compositions for Inhalation |
| 01/21/2010 | US20100015235 Compositions and methods for treating multiple sclerosis |
| 01/21/2010 | US20100015215 Use of Glycolipids as Adjuvants |
| 01/21/2010 | US20100015214 Novel Trans-Adjuvant System |
| 01/21/2010 | US20100015212 Immunogenic bacterial vesicles with outer membrane proteins |
| 01/21/2010 | US20100015211 Combination Approaches For Generating Immune Responses |
| 01/21/2010 | US20100015182 Coccidiosis vaccines |
| 01/21/2010 | US20100015181 Vaccine formulation |
| 01/21/2010 | US20100015180 Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses |
| 01/21/2010 | US20100015179 Attenuation of encephalitogenic alphavirus and uses thereof |
| 01/21/2010 | US20100015178 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/21/2010 | US20100015177 Method for Preserving Viral Particles |
| 01/21/2010 | US20100015176 Settings for recombinant adenoviral-based vaccines |
| 01/21/2010 | US20100015175 Vaccine |
| 01/21/2010 | US20100015173 Coiled-coil lipopeptide helical bundles and synthetic virus-like particles |